Detailed Information
Cited 8 time in 
Cited 9 time in 
Cited 9 time in
Metadata Downloads
Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
- Authors
- Cheon, Yun-Hong; Kim, Moon Jin; Kang, Min Gyu; Kim, Hee Jin; Lee, Sang Su; Kim, Cha Young; Jeon, Dae-Hong; Kim, Yu Eun; Lee, Gyeong-Won
- Issue Date
- Jul-2011
- Publisher
- 연세대학교의과대학
- Keywords
- Lung neoplasm; intestinal fistula; erlotinib
- Citation
- Yonsei Medical Journal, v.52, no.4, pp 695 - 698
- Pages
- 4
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Yonsei Medical Journal
- Volume
- 52
- Number
- 4
- Start Page
- 695
- End Page
- 698
- ISSN
- 0513-5796
1976-2437
- Abstract
- Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
- Files in This Item
- There are no files associated with this item.
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.